2023 ICD-10-CM Diagnosis Code R97.21

Rising PSA following treatment for malignant neoplasm of prostate

    2017 - New Code 2018 2019 2020 2021 2022 2023 Billable/Specific Code Adult Dx (15-124 years) Male Dx Questionable As Admission Dx
  • R97.21 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • Short description: Rising PSA fol treatment for malignant neoplasm of prostate
  • The 2023 edition of ICD-10-CM R97.21 became effective on October 1, 2022.
  • This is the American ICD-10-CM version of R97.21 - other international versions of ICD-10 R97.21 may differ.
ICD-10-CM Coding Rules
  • R97.21 is applicable to adult patients aged 15 - 124 years inclusive.
  • R97.21 is applicable to male patients.
  • R97.21 is not usually sufficient justification for admission to an acute care hospital when used a principal diagnosis.
The following code(s) above R97.21 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to R97.21:
  • R00-R99
    2023 ICD-10-CM Range R00-R99

    Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

    • This chapter includes symptoms, signs, abnormal results of clinical or other investigative procedures, and ill-defined conditions regarding which no diagnosis classifiable elsewhere is recorded.
    • Signs and symptoms that point rather definitely to a given diagnosis have been assigned to a category in other chapters of the classification. In general, categories in this chapter include the less well-defined conditions and symptoms that, without the necessary study of the case to establish a final diagnosis, point perhaps equally to two or more diseases or to two or more systems of the body. Practically all categories in the chapter could be designated 'not otherwise specified', 'unknown etiology' or 'transient'. The Alphabetical Index should be consulted to determine which symptoms and signs are to be allocated here and which to other chapters. The residual subcategories, numbered .8, are generally provided for other relevant symptoms that cannot be allocated elsewhere in the classification.
    • The conditions and signs or symptoms included in categories R00-R94 consist of:
    • (a) cases for which no more specific diagnosis can be made even after all the facts bearing on the case have been investigated;
    • (b) signs or symptoms existing at the time of initial encounter that proved to be transient and whose causes could not be determined;
    • (c) provisional diagnosis in a patient who failed to return for further investigation or care;
    • (d) cases referred elsewhere for investigation or treatment before the diagnosis was made;
    • (e) cases in which a more precise diagnosis was not available for any other reason;
    • (f) certain symptoms, for which supplementary information is provided, that represent important problems in medical care in their own right.
    Type 2 Excludes
    • abnormal findings on antenatal screening of mother (O28.-)
    • certain conditions originating in the perinatal period (P04-P96)
    • signs and symptoms classified in the body system chapters
    • signs and symptoms of breast (N63, N64.5)
    Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
  • R97
    ICD-10-CM Diagnosis Code R97

    Abnormal tumor markers

      2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Applicable To
    • Elevated tumor associated antigens [TAA]
    • Elevated tumor specific antigens [TSA]
    Abnormal tumor markers
ICD-10-CM R97.21 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
  • 947 Signs and symptoms with mcc
  • 948 Signs and symptoms without mcc

Convert R97.21 to ICD-9-CM

Code History
  • 2017 (effective 10/1/2016): New code
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
Code annotations containing back-references to R97.21:
  • Use Additional: C61
    ICD-10-CM Diagnosis Code C61

    Malignant neoplasm of prostate

      2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code Male Dx
    Type 1 Excludes
    • malignant neoplasm of seminal vesicle (C63.7)
    Use Additional
    • code, if applicable, to identify:
    • hormone sensitivity status (Z19.1-Z19.2)
    • rising PSA following treatment for malignant neoplasm of prostate (R97.21)

Diagnosis Index entries containing back-references to R97.21:
  • Rising, PSA following treatment for malignant neoplasm of prostate R97.21

ICD-10-CM Codes Adjacent To R97.21
R94.4 Abnormal results of kidney function studies
R94.5 Abnormal results of liver function studies
R94.6 Abnormal results of thyroid function studies
R94.7 Abnormal results of other endocrine function studies
R94.8 Abnormal results of function studies of other organs and systems
R97 Abnormal tumor markers
R97.0 Elevated carcinoembryonic antigen [CEA]
R97.1 Elevated cancer antigen 125 [CA 125]
R97.2 Elevated prostate specific antigen [PSA]
R97.20 Elevated prostate specific antigen [PSA]
R97.21 Rising PSA following treatment for malignant neoplasm of prostate
R97.8 Other abnormal tumor markers
R99 Ill-defined and unknown cause of mortality
S00 Superficial injury of head
S00.0 Superficial injury of scalp
S00.00 Unspecified superficial injury of scalp
S00.00XA …… initial encounter
S00.00XD …… subsequent encounter
S00.00XS …… sequela
S00.01 Abrasion of scalp
S00.01XA …… initial encounter

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.